Background Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking …
JR Durkee-Shock, MD Keller - Annals of Allergy, Asthma & Immunology, 2022 - Elsevier
Objective To update clinicians on current evidence regarding the immunogenicity and safety of coronavirus disease 2019 (COVID-19) vaccines in patients with inborn errors of immunity …
Background SARS-CoV-2 vaccination is recommended in patients with inborn errors of immunity (IEIs); however, little is known about immunogenicity and safety in these patients …
D Amodio, A Ruggiero, M Sgrulletti, C Pighi… - Frontiers in …, 2021 - frontiersin.org
Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global pandemic we are facing. Immunocompromised patients represent a vulnerable population at …
Background There is uncertainty about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI) …
Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort …
T Milota, M Sobotkova, J Smetanova… - Frontiers in …, 2022 - frontiersin.org
Despite the progress in the understanding how COVID-19 infection may impact immunocompromised patients, the data on inborn errors of immunity (IEI) remain limited and …
M Oyaert, MA De Scheerder, S Van Herrewege… - Frontiers in …, 2022 - frontiersin.org
Background Immunocompromised patients are at increased risk of severe COVID-19 and impaired vaccine response. In this observational prospective study, we evaluated …
K Xu, L Dai, GF Gao - International Immunology, 2021 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine …